NASDAQ:TENX Tenax Therapeutics (TENX) Stock Price, News & Analysis $1.82 +0.13 (+7.40%) As of 11:40 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Tenax Therapeutics Stock (NASDAQ:TENX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tenax Therapeutics alerts:Sign Up Key Stats Today's Range$1.65▼$1.8350-Day Range$1.36▼$2.1352-Week Range$1.31▼$19.40Volume811,150 shsAverage Volume2.20 million shsMarket Capitalization$67.92 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingHold Company Overview Tenax Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and pulmonary diseases. The company’s research programs are aimed at addressing conditions with significant unmet medical needs, including pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). Tenax’s lead product candidate is TNX-103, an oral formulation of levosimendan. Levosimendan is a calcium sensitizer and potassium-channel activator that has been approved for certain heart-failure indications outside the United States. Tenax is evaluating the therapy for potential use in patients with PH-HFpEF, an area in which treatment options remain limited. The company’s activities are primarily focused on clinical development and regulatory advancement in the United States. Tenax Therapeutics was formerly known as Oxygen Biotherapeutics and adopted its current name as it shifted its focus toward pharmaceutical development in cardiovascular and pulmonary medicine.AI Generated. May Contain Errors. Read More Tenax Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreTENX MarketRank™: 3.88645989889 of 5 starsTenax Therapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 145th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingTenax Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 1 strong buy rating, 3 buy ratings, 5 hold ratings, and 1 sell rating.Upside PotentialTenax Therapeutics has a consensus price target of $14.00, representing about 671.3% upside from its current price of $1.82.Amount of Analyst CoverageTenax Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tenax Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tenax Therapeutics are expected to decrease in the coming year, from ($1.35) to ($1.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tenax Therapeutics is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tenax Therapeutics is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTenax Therapeutics has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.66% of the float of Tenax Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenax Therapeutics has a short interest ratio ("days to cover") of 3.22, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tenax Therapeutics has recently increased by 0.66%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTenax Therapeutics does not currently pay a dividend.Dividend GrowthTenax Therapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.02 News SentimentTenax Therapeutics has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Tenax Therapeutics this week, compared to 4 articles on an average week.Search Interest4 people have searched for TENX on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership4.0 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of Tenax Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $6,388,279.00 in company stock, which represents 9.4050% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Tenax Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,388,279.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.81% of the stock of Tenax Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions1.67% of the stock of Tenax Therapeutics is held by institutions.Read more about Tenax Therapeutics' insider trading history. Receive TENX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TENX Stock News HeadlinesTENX DEADLINE: Levi & Korsinsky Reminds Tenax Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline1 hour ago | globenewswire.comINVESTOR DEADLINE: Tenax Therapeutics, Inc. (TENX) Investors with Substantial Losses May Seek to Lead Class Action Lawsuit Before December 28, 2026 Deadline2 hours ago | prnewswire.comMy prediction for December 8thElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 9 at 1:00 AM | Behind the Markets (Ad)What Does Tenax Therapeutics, Inc.'s 89.77% Stock Drop Mean for Investors? The Law Offices of Howard G.2 hours ago | prnewswire.comTenax Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – TENX3 hours ago | businesswire.comTENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS LawNovember 9 at 3:32 AM | prnewswire.comSHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Tenax Therapeutics, Inc. (NASDAQ: TENX) — Investors Who Suffered Losses Are Encouraged to Contact the FirmNovember 8 at 11:00 AM | globenewswire.comInsider Buying: Tenax Therapeutics (NASDAQ:TENX) Major Shareholder Buys $406,947.20 in StockOctober 22, 2026 | insidertrades.comSee More Headlines TENX Stock Analysis - Frequently Asked Questions How have TENX shares performed this year? Tenax Therapeutics' stock was trading at $12.19 at the start of the year. Since then, TENX shares have decreased by 85.1% and is now trading at $1.8150. How were Tenax Therapeutics' earnings last quarter? Tenax Therapeutics, Inc. (NASDAQ:TENX) announced its quarterly earnings results on Thursday, November, 5th. The specialty pharmaceutical company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.04. When did Tenax Therapeutics' stock split? Tenax Therapeutics shares reverse split on Wednesday, January 3rd 2024.The 1-80 reverse split was announced on Wednesday, January 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are Tenax Therapeutics' major shareholders? Top institutional investors of Tenax Therapeutics include State of Alaska Department of Revenue (0.13%), Alps Advisors Inc. (0.13%) and Russell Investments Group Ltd. (0.06%). Insiders that own company stock include Adar1 Capital Management, Llc, Declan Doogan, Christopher Thomas Giordano, Stuart Rich and Thomas Mcgauley. View institutional ownership trends. How do I buy shares of Tenax Therapeutics? Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tenax Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tenax Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Tonix Pharmaceuticals (TNXP), Advanced Micro Devices (AMD), Bollinger Innovations (BINI), FuelCell Energy (FCEL) and Micron Technology (MU). Company Calendar Last Earnings11/05/2026Today11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 TENX's financial health is in the Red zone, according to TradeSmith. TENX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TENX CIK34956 Webwww.tenaxthera.com Phone919-855-2100Fax919-855-2133Employees16Year Founded1967Price Target and Rating Average Price Target for Tenax Therapeutics$14.00 High Price Target$50.00 Low Price Target$4.00 Potential Upside/Downside+671.3%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$52.60 million Net MarginsN/A Pretax MarginN/A Return on Equity-60.64% Return on Assets-56.52% Debt Debt-to-Equity RatioN/A Current Ratio15.07 Quick Ratio15.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.42 per share Price / Book0.17Miscellaneous Outstanding Shares37,424,000Free Float40,614,000Market Cap$67.92 million OptionableOptionable Beta0.99 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:TENX) was last updated on 11/9/2026 by MarketBeat.com Staff. From Our PartnersTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredElon's Terrifying Warning: America Is "1,000% Going Bankrupt"The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...American Hartford Gold | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredWhat Elon Musk's Cybercab Reveal Could Mean for InvestorsJeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenax Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
